Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Health,
Industry
|
Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector.
|
Policies or Program
|
Health,
Industry,
International Trade
|
Discussions with officials regarding the COVID-19 pandemic.
|
Policies or Program
|
Health
|
Health Canada regarding the development of a national pharmacare strategy.
|
Policies or Program
|
Health,
Industry
|
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
|
Policies or Program,
Regulation
|
Health,
Industry
|
Health Canada with respect to the process for the approval and renewal of foreign sites for Drug Establishment License (DEL) holders. Related guidance documents include the Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080), the Guidance on Drug Establishment Licences and Drug Establishment Licensing Fees (GUI-0002) and the Guidance on Good Manufacturing Practices for Active Pharmaceutical Ingredients (GUI-0104).
|
Policies or Program
|
Health,
Industry
|
Health Canada with respect to user fees for therapeutic product regulatory programs.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Industry
|
Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
|
Policies or Program
|
Health,
Industry,
International Trade
|
Participate in Government of Canada consultations with respect to the Regulatory Cooperation Council.
|
Policies or Program,
Regulation
|
Health,
Industry
|
Participation in Competition Bureau consultations with respect to pharmaceuticals.
|
Policies or Program
|
Health
|
Proposals related to Health Canada's Identical Medicinal Ingredient Policy.
|
Policies or Program
|
Health
|
Proposals to enhance transparency of the Health Canada Reconsiderations Policy for drug submissions.
|
Policies or Program
|
Health,
Industry
|
Provide input into policy discussions with respect to the potential implementation of a national pharmacare program.
|
Legislative Proposal, Bill or Resolution
|
Health,
Industry,
International Trade
|
Provide input into the Government of Canada's implementation of the Canada-United States-Mexico Agreement (CUSMA).
|
Legislative Proposal, Bill or Resolution
|
Industry,
International Trade
|
Provide input into the Government of Canada's negotiations regarding trade negotiations with respect to pharmaceuticals, counterfeit medicines, and intellectual property. This includes trade discussions between Canada and the United Kingdom.
|
Legislative Proposal, Bill or Resolution
|
Industry
|
Provide input into the Patented Medicine Prices Review Board (PMPRB) consultations regarding its Policies, Guidelines and Procedures.
|
Policies or Program
|
Health,
Industry
|
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Health,
Industry
|
Providing input with respect to the approval pathway for biosimilar medicines by Health Canada.
|
Policies or Program
|
Health,
Industry
|
Seeking harmonization of regulatory regimes and administrative processes nationally and internationally.
|
Policies or Program
|
Health,
International Trade
|
To encourage the Government of Canada to continue to participate in truly international discussions with respect to effective measures to combat substandard and falsified medicines in Canada and around the world.
|
Policies or Program
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Discussions with officials regarding the COVID-19 pandemic.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health Canada regarding the development of a national pharmacare strategy.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
|
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health Canada with respect to the process for the approval and renewal of foreign sites for Drug Establishment License (DEL) holders. Related guidance documents include the Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080), the Guidance on Drug Establishment Licences and Drug Establishment Licensing Fees (GUI-0002) and the Guidance on Good Manufacturing Practices for Active Pharmaceutical Ingredients (GUI-0104).
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health Canada with respect to user fees for therapeutic product regulatory programs.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Participate in Government of Canada consultations with respect to the Regulatory Cooperation Council.
|
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Participation in Competition Bureau consultations with respect to pharmaceuticals.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Proposals related to Health Canada's Identical Medicinal Ingredient Policy.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Proposals to enhance transparency of the Health Canada Reconsiderations Policy for drug submissions.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Provide input into policy discussions with respect to the potential implementation of a national pharmacare program.
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Provide input into the Government of Canada's implementation of the Canada-United States-Mexico Agreement (CUSMA).
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Provide input into the Government of Canada's negotiations regarding trade negotiations with respect to pharmaceuticals, counterfeit medicines, and intellectual property. This includes trade discussions between Canada and the United Kingdom.
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Provide input into the Patented Medicine Prices Review Board (PMPRB) consultations regarding its Policies, Guidelines and Procedures.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Providing input with respect to the approval pathway for biosimilar medicines by Health Canada.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Seeking harmonization of regulatory regimes and administrative processes nationally and internationally.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
To encourage the Government of Canada to continue to participate in truly international discussions with respect to effective measures to combat substandard and falsified medicines in Canada and around the world.
|
Policies or Program
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Date | DPOH, Position Title | Government Institution | Subject Matters |
---|---|---|
2024-09-03 |
|
Health |
2024-06-20 |
|
Industry |
2024-06-19 |
|
Industry |
2024-06-17 |
|
Industry |
2024-05-15 |
|
Health, Industry |
2024-05-07 |
|
Health, Industry |
2024-05-01 |
|
Health, Industry |
2024-05-01 |
|
Health, Industry |
2024-05-01 |
|
Industry |
2024-02-27 |
|
Health, Industry |
2023-12-12 |
|
Health, Industry |
2023-11-08 |
|
Health, Industry |